ALKS Alkermes plc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Pharmaceutical development and licensing for specialty medicines, with substantial collaboration and royalty revenues from partners Janssen and Biogen
• • Strategic shift: Sale of Athlone manufacturing facility in May 2024 and transition of VUMERITY manufacturing to Biogen's subcontractor completed August 2025

Risk Factors

• • Regulatory risk: potential increased tax liability of ~$70M on $965.7M in cumulative unremitted U.S. earnings upon repatriation subject to foreign tax credits and withholding
• • Macroeconomic threat: $1.525B senior secured term loans due 2031 with interest margins of 1.75%-2.75% increase financing costs and leverage post-Avadel Acquisition

Management Discussion & Analysis

• • Revenue product sales, net $1,184.6M up $101.1M YoY from $1,083.5M, driven by LYBALVI (+$66.7M) and ARISTADA (+$23.8M) growth
• • Manufacturing and royalty revenues declined $182.8M to $291.3M, mainly from long-acting INVEGA products down $126.9M

Management Discussion & Analysis

• • Revenue increased $16.0M QoQ, driven by higher product sales, partially offset by lower manufacturing and royalty revenue
• • Net income from continuing operations $82.8M vs $92.8M YoY Q3, net income decline of $10.0M

Risk Factors

• • New acquisition risk from Avadel deal pending H1 2026, subject to shareholder, court, and US antitrust approvals
• • Most material update: Added $1.2B Bridge Credit Facility for Avadel acquisition, with leverage covenants and default risks

What are the latest ALKS SEC filings in 2026?

Alkermes plc. (ALKS) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 28, 2025, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ALKS file its most recent 10-K annual report?

Alkermes plc. (ALKS) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ALKS 10-Q quarterly reports?

Alkermes plc. (ALKS)'s most recent 10-Q quarterly report was filed on October 28, 2025. SignalX displays every ALKS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ALKS filed recently?

Alkermes plc. (ALKS)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ALKS insider trading activity (Form 4)?

SignalX aggregates every ALKS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ALKS file with the SEC?

Alkermes plc. (ALKS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ALKS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Alkermes plc. (ALKS).

What is ALKS's SEC CIK number?

Alkermes plc. (ALKS)'s SEC CIK (Central Index Key) number is 1520262. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1520262 to look up all ALKS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ALKS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Alkermes plc. (ALKS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.